title: A Val193Met mutation in GPIIIa results in a GPIIb/IIIa receptor with a constitutively high affinity for a small ligand.
abstract: We have identified a patient designated as (GTa) with Glanzmann's Thrombasthenia (GT) diagnosed on the basis of a prolonged bleeding time and failure of the patient's platelets to aggregate. The number of glycoprotein (GP)IIb/IIIa receptors on the platelet surface was 37% of normal and those receptors displayed a defect in soluble fibrinogen binding. Nevertheless, GTa platelets showed increased adhesion to solid-phase fibrinogen and binding affinity for the RGD-mimetic (3)H-SC52012, a non-peptide GPIIb/IIIa antagonist. Dithiothreitol (DTT) and ADP enhanced the affinity for [(3)H]-SC52012 in normal platelets, but had little effect in GTa platelets. These findings suggested that GTa platelets were locked in an altered affinity state. Genetic analysis showed that GTa was a compound heterozygote for the GPIIIa gene. One allele showed a deletion at the 3' end of exon 3 resulting in a premature stop codon. The second GPIIIa allele had a G to A transition at nucleotide 577, resulting in a Val193Met substitution. HEK 293T cells transfected with mutant GPIIb/IIIaV193M bound [(3)H]-SC52012 with a higher affinity than wild-type GPIIb/IIIa, and this was not increased by DTT. The mutant receptor distinguishes between platelet adhesion and aggregation, and demonstrates the phenotype that may be expected when platelet aggregation alone is inhibited.
authors.affiliation: Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, Dublin, Ireland.
authors.forename: J
authors.initials: J
authors.lastname: Fullard
authors.forename: R
authors.initials: R
authors.lastname: Murphy
authors.forename: S
authors.initials: S
authors.lastname: O'Neill
authors.forename: N
authors.initials: N
authors.lastname: Moran
authors.forename: B
authors.initials: B
authors.lastname: Ottridge
authors.forename: D J
authors.initials: DJ
authors.lastname: Fitzgerald
mesh_terms: D000244:Adenosine Diphosphate / Q000494:pharmacology; D000328:Adult; D001792:Blood Platelets / Q000187:drug effects; D002460:Cell Line; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D010974:Platelet Aggregation; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000235:genetics* / Q000378:metabolism; D017354:Point Mutation; D011485:Protein Binding; D011869:Radioligand Assay; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013329:Structure-Activity Relationship; D013601:T-Lymphocytes / Q000378:metabolism; D013915:Thrombasthenia / Q000097:blood / Q000235:genetics*; D014162:Transfection
chemical_list: D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000244:Adenosine Diphosphate; D005340:Fibrinogen